Back to top

oncology-screening: Archive

Zacks Equity Research

Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why

Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.

PFENegative Net Change ADMAPositive Net Change FGENNegative Net Change CRDFNegative Net Change

Zacks Equity Research

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

AMGNNegative Net Change SRPTNegative Net Change BGNEPositive Net Change CRSPPositive Net Change